The NHS has agreed on a deal for life-saving treatment for metachromatic leukodystrophy that will offer babies and young children the prospect of a normal life.
The revolutionary gene therapy treatment named Libmeldy is used to treat metachromatic leukodystrophy is reportedly the most expensive drug in the world. Metachromatic leukodystrophy causes severe damage to the child’s nervous system and organs, resulting in a life expectancy of between five and eight years.
This deal is part of the NHS Long Term Plan, a plan drawn up by frontline staff, patient groups, and national experts to create a service fit for the future. The aim is to provide cutting-edge treatments and therapies to patients.
Read more at: https://www.healtheuropa.eu/nhs-to-roll-out-new-gene-therapy-for-metachromatic-leukodystrophy/113299/
